Trials / Completed
CompletedNCT00160667
A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)
An Exploratory, Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Study, for the Assessment of Efficacy, Safety and Tolerability of Ucb 34714 50 mg Oral Capsules in b.i.d. Administration at the Doses of 200 mg/Day and 400 mg/Day, in Subjects (at Least 18 Years Old) Suffering From Post Herpetic Neuralgia (PHN)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study will assess efficacy, safety and tolerability of brivaracetam in post-herpetic neuralgia (PHN). Duration of 7 weeks divided into 3 periods with no up-titration, nor down-titration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Daily oral dose of two equal intakes. |
| DRUG | Brivaracetam | Daily oral dose of two equal intakes. |
Timeline
- Start date
- 2004-10-11
- Primary completion
- 2006-01-05
- Completion
- 2006-01-05
- First posted
- 2005-09-12
- Last updated
- 2019-01-31
- Results posted
- 2019-01-31
Locations
50 sites across 10 countries: Belgium, Bulgaria, Czechia, France, Germany, Poland, Serbia, Slovakia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00160667. Inclusion in this directory is not an endorsement.